We are live on ! Find out more

Faeth Therapeutics

FTH

Market cap $508M

19.65 USD

+0.42

2.18%

At close Updated Nov 3, 4:00 PM EST

Pre-market

After hours

19.65

0.00

0%

1 day

2.18%

5 days

0.77%

1 month

-27.49%

3 months

-28.13%

6 months

-26.4%

Year to date

103.63%

1 year

128.22%

5 years

-88.95%

10 years

-94.8%

About: Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.

Employees: 29

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 17.6%

Neutral 82.4%

Negative 0%

Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced financial results for the quarter ended September 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. “Since our last quarterly update, we presented PK/PD analysis that informed the PIKTOR dose in our Phase 2 PIK-201 trial and received Fast Track designation for PIKT.

Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates

Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced the appointment of Adam Schayowitz, Ph.D., MBA, to its Board of Directors. Dr. Schayowitz is Executive Vice President and Head of Research and Development at Zymeworks (Nasdaq: ZYME). Dr. Schayowitz has nearly 20 years of experience in oncology drug development and has led dozens of global deve.

Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors

Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled “Characterising the efficacy of multi-node PI3K/AKT/mTOR pathway inhibition with serabelisib and sapanisertib (PIKTOR) in combination with SERDs and a CDK4/6.

Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an aggregate of 17,000 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective October 19, 2026 pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment.

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will present preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.The poster will be presented on Friday, October 23, and will showcase preclinical data intended to inform the ongoing development of PIKTOR in the FTH-PIK-101 Phase 1b/2 trial.

Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026

Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion

I am initiating Faeth Therapeutics with a "Buy" rating following its acquisition, name change, and $200M private placement. Company's lead asset, PIKTOR, targets multi-node PAM pathway alterations in endometrial cancer and HR+/HER2- breast cancer, with key phase 2 and 1b/2 data catalysts ahead. Topline results for PIKTOR in 2nd-line advanced endometrial cancer are expected by year-end 2026, with interim breast cancer data in 2027.

Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion

Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways, today announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026.“Karen helped shape the scientific thesis this company was built on, and she has been a trusted advisor to Faeth since its founding,” said Anand Parikh, Chairm.

Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors

Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 6, 2026 at 10:00 AM ET featuring Marcus Goncalves, MD, PhD (NYU Langone Health & Scientific Co-founder, Faeth Therapeutics), who will join company management to discuss the PAM (PI3K/AKT/mTOR) pathway in human can.

Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026

Zacks Investment Research

What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?

Does Faeth Therapeutics, Inc. (FTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?

Faeth Therapeutics to Participate in Upcoming September Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences:Wells Fargo 21st Annual Healthcare ConferenceTuesday, September 8, 20261x1 investor meetingsBoston, MACiti Biopharma Back to School SummitWednesday, September 9, 2026Fireside chat at 10:00 a.m. ETNew York, NYCantor G.

Faeth Therapeutics to Participate in Upcoming September Investor Conferences

See News Rankings

Price charts implemented using Lightweight Charts™